Cumberland Pharmaceuticals Inc. announced top-line results from its Phase 2a ASSIST-SSc clinical trial for its drug candidate, ifetroban. The study evaluated oral ifetroban in patients with systemic sclerosis, a rare disease, with the results supporting the drug's safety and tolerability profile.
Key Details
- Event: Announcement of top-line results for the Phase 2a ASSIST-SSc trial.
- Drug: Oral ifetroban for the treatment of systemic sclerosis (SSc).
- Key Finding: The trial results support the safety and tolerability of ifetroban in this rare disease patient population.